The 200,000 sq. ft. facility will manufacture elastomeric components. But, why the US? Williamson said, “the US has shown strong double-digit growth in biologics … and almost all are injectables, which will require components manufactured by Datwyler.”
“The US remains the fasted growing regions of biologic and biosimilar developments,” she added. “We would like to further strengthen our position here.”
However, the company’s global footprint is also about to increase as it will roll out a new healthcare offering strategy.
Williams explained the three care programs will enable access to offerings in “an easy and intuitive way.” The care programs include, “Bio Care, Pharma Care, and Med Care.” Additional details on the programs will be released later this week.
“This is a huge strategic investment from Datwyler,” concluded Williamson. “The largest in our company history.”